Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis

Langerhans cell histiocytosis (LCH) is an inflammatory myeloid malignancy in the “L-group” histiocytosis. Mitogen-activated protein kinase (MAPK) pathway activating mutations are detectable in nearly all LCH lesions. However, the pathogenic roles of MAPK pathway activation in the development of hist...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Xue-min, Li, Jian, Cao, Xin-xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764551/
https://www.ncbi.nlm.nih.gov/pubmed/36536400
http://dx.doi.org/10.1186/s12964-022-00917-0
_version_ 1784853296270278656
author Gao, Xue-min
Li, Jian
Cao, Xin-xin
author_facet Gao, Xue-min
Li, Jian
Cao, Xin-xin
author_sort Gao, Xue-min
collection PubMed
description Langerhans cell histiocytosis (LCH) is an inflammatory myeloid malignancy in the “L-group” histiocytosis. Mitogen-activated protein kinase (MAPK) pathway activating mutations are detectable in nearly all LCH lesions. However, the pathogenic roles of MAPK pathway activation in the development of histiocytosis are still elusive. This review will summarize research concerning the landscape and pathogenic roles of MAPK pathway mutations and related treatment opportunities in Langerhans cell histiocytosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-022-00917-0.
format Online
Article
Text
id pubmed-9764551
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97645512022-12-21 Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis Gao, Xue-min Li, Jian Cao, Xin-xin Cell Commun Signal Review Langerhans cell histiocytosis (LCH) is an inflammatory myeloid malignancy in the “L-group” histiocytosis. Mitogen-activated protein kinase (MAPK) pathway activating mutations are detectable in nearly all LCH lesions. However, the pathogenic roles of MAPK pathway activation in the development of histiocytosis are still elusive. This review will summarize research concerning the landscape and pathogenic roles of MAPK pathway mutations and related treatment opportunities in Langerhans cell histiocytosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-022-00917-0. BioMed Central 2022-12-19 /pmc/articles/PMC9764551/ /pubmed/36536400 http://dx.doi.org/10.1186/s12964-022-00917-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Gao, Xue-min
Li, Jian
Cao, Xin-xin
Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis
title Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis
title_full Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis
title_fullStr Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis
title_full_unstemmed Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis
title_short Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis
title_sort signaling pathways, microenvironment, and targeted treatments in langerhans cell histiocytosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764551/
https://www.ncbi.nlm.nih.gov/pubmed/36536400
http://dx.doi.org/10.1186/s12964-022-00917-0
work_keys_str_mv AT gaoxuemin signalingpathwaysmicroenvironmentandtargetedtreatmentsinlangerhanscellhistiocytosis
AT lijian signalingpathwaysmicroenvironmentandtargetedtreatmentsinlangerhanscellhistiocytosis
AT caoxinxin signalingpathwaysmicroenvironmentandtargetedtreatmentsinlangerhanscellhistiocytosis

Ejemplares similares